TALICIA
Peakomeprazole magnesium, amoxicillin and rifabutin
NDAORALCAPSULE, DELAYED RELEASEPriority Review
Approved
Nov 2019
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TALICIA is a fixed-dose combination oral capsule containing omeprazole magnesium, amoxicillin, and rifabutin for the treatment of Helicobacter pylori infection. This triple-therapy regimen combines a proton pump inhibitor with two antimicrobials to eradicate the bacterium. The formulation uses delayed-release capsule technology to optimize bioavailability and therapeutic efficacy.
$0.003BPart D
PeakStable
15.6 years to LOEProduct is in peak revenue phase with modest Medicare utilization, suggesting a stable but niche commercial footprint with limited team expansion opportunities.
Mechanism of Action
Pharmacologic Class:
Rifamycin Antimycobacterial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TALICIA offers stable career opportunities in commercial and medical affairs for professionals focused on niche, specialist-driven products in infectious disease. The product's peak-stage status and minimal competitive pressure suggest a focused team environment without high-growth hiring, but with strong job security through patent protection.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.